1 Carotid body dysregulation contributes to the enigma of long COVID

- 2 Ahmed El-Medany^{*1,2,3}, Zoe H Adams^{*1}, Hazel C Blythe^{*1}, Katrina A Hope^{1,4}, Adrian
- 3 H Kendrick^{1,5}, Ana Paula Abdala Sheikh¹, Julian FR Paton⁶, Angus K Nightingale^{1,3},
- 4 Emma C Hart¹
- 5 *Contributed equally to fist authorship.
- 6 ¹ School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol,
- 7 UK.
- 8 ² Department of Cardiology, Southmead Hospital, North Bristol NHS Trust, Bristol,
- 9 UK.
- ³ Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation
- 11 Trust, Bristol, UK.
- ⁴ Department of Anaesthetics, Southmead Hospital, North Bristol NHS Trust, Bristol,
 UK.
- ⁵ Department of Respiratory Medicine, University Hospitals Bristol and Weston NHS
- 15 Foundation Trust, Bristol, UK.
- ⁶ Manaaki Manawa, The Centre for Heart Research, University of Auckland,
- 17 Auckland, New Zealand.

18

19 Abstract

20 The symptoms of long COVID, which include fatigue, breathlessness, dysregulated 21 breathing, and exercise intolerance, have unknown mechanisms. These symptoms 22 are also observed in heart failure and are partially driven by increased sensitivity of 23 the carotid chemoreflex. As the carotid body has an abundance of ACE2 (the cell 24 entry mechanism for SARS-CoV-2), we investigated whether carotid chemoreflex 25 sensitivity was elevated in participants with long COVID. During cardiopulmonary 26 exercise testing, the V_E/VCO_2 slope (a measure of breathing efficiency) was higher 27 in the long COVID group than in the controls, indicating excessive hyperventilation. 28 The hypoxic ventilatory response, which measures carotid chemoreflex sensitivity, 29 was increased in long COVID participants and correlated with the V_F/VCO_2 slope, 30 suggesting that excessive hyperventilation may be related to carotid body 31 hypersensitivity. Therefore, the carotid chemoreflex is sensitized in long COVID and 32 may explain dysregulated breathing and exercise intolerance in these participants. 33 Tempering carotid body excitability may be a viable treatment option for long COVID 34 patients.

35 Introduction

36 Long COVID (post-COVID-19 syndrome), is a multi-organ, often debilitating 37 condition associated with a range of symptoms. The UK's National Institute for 38 Health Care and Excellence (NICE) defines long COVID as ongoing symptoms 39 lasting for 12 or more weeks after initial SARS-CoV-2 infection, without alternative 40 explanations¹. The estimated incidence of long COVID varies, and is reported to be up to 41% of non-hospitalised cases ^{2 3 4} and up to 76% of hospitalised cases^{5 6}. The 41 42 prevalence decreases in vaccinated populations⁷. In January 2023, 2 million people 43 self-reported long COVID symptoms in the UK, with 77% experiencing adverse effects in their daily activities⁸. Persistent symptoms include chronic fatigue, 'brain 44 45 fog,' cognitive impairment and memory loss, dyspnoea at rest and on exertion, 46 exercise intolerance, orthostatic intolerance, inappropriate postural tachycardia, and episodic hyperadrenergic surges^{4,9,10}. A meta-analysis of 63 studies worldwide, with 47 48 a total COVID-19 population of 257,348, reported that between 3-6 and 9-12 months 49 post-infection, fatigue and dyspnoea were the most reported symptoms, with a 50 prevalence of 32-47% and 21-25% respectively¹¹. Despite the prevalence of long 51 COVID and severely disabling symptoms there are no treatment strategies available. 52 Thus, it is crucial to identify the mechanisms involved in long COVID to inform 53 urgently needed therapy. It is likely that mechanisms depend on the severity of the 54 original infection and are different for hospitalised (e.g. long term segualae from 55 intensive care and intubation/ventilation) versus non-hospitalised patients who had mild to moderate initial symptoms. 56

57 Currently, the exact mechanisms driving long COVID in non-hospitalised patients remain unknown but are likely to be multiple^{12,13}. Studies have shown that exercise 58 59 intolerance and disorganised breathing or breathing inefficiency during exercise are key features of long COVID¹⁴⁻¹⁷ even in patients who have normal lung function and 60 no evidence of gas exchange abnormalities¹⁶. The carotid bodies are key oxygen, 61 62 carbon dioxide and pH sensing organs that control ventilation, dyspnoea, and the circulation at rest and during exercise in health and disease^{18,19}. In fact, in chronic 63 heart failure the carotid chemoreflex becomes chronically sensitised as a 64 compensatory mechanism, and is associated with a worse prognosis²⁰, exertional 65 dyspnoea, dysfunctional or inefficient breathing, and poor exercise tolerance²¹, 66 67 similar to symptoms in patients with long COVID who do not have heart failure.

68 SARS-CoV-2 infects host cells via binding of its receptor-binding domain to the membrane bound angiotensin-converting enzyme 2 (ACE2)²². ACE2 is abundant in 69 the carotid bodies²³. A role of the carotid chemoreflex in the acute phase of the 70 infection is supported by reports of silent hypoxia^{23,24}, SARS-CoV-2 invasion of 71 72 glomus cells (main oxygen sensing cells) and microembolism within the small arteries suppling blood to the carotid body^{25,26}. The carotid bodies express their own 73 renin-angiotensin system^{27,28}, where normal functioning is dependent on the balance 74 of ACE1 and ACE2²⁷. Disruption of this local system causes increased carotid 75 chemoreflex activity ^{28,29}. Thus, disturbances in the carotid body following SARS-76 77 CoV-2 infection; by viral invasion, blood flow disruption and local immune responses 78 could cause chemoreceptive dysfunction, by increasing local ACE1/ACE2 imbalance 79 (in favour of higher ACE1 expression versus ACE2) and angiotensin II receptor stimulation^{25,30}. 80 81 We propose that carotid body dysfunction occurs in long COVID, which contributes 82 to dysregulation of ventilation and cardiovascular control, especially during exercise. 83 Therefore, we conducted a case-control study to determine whether carotid 84 chemoreflex sensitivity is elevated in non-hospitalised patients with long COVID and 85 whether this could help to explain impairments in exercise tolerance and 86 dysregulated breathing reported during exercise in non-hospitalised patients with 87 ongoing symptoms. We hypothesised that long COVID patients would exhibit 88 increased hypoxic ventilatory responses at rest and poorer ventilatory efficiency

89 during exercise compared to controls.

90

91 Results

92 Participants

Supplementary Figure 1 shows recruitment, screening, cases excluded and the final sample size. Sixty-four individuals contacted the group about the study, and all were sent a participant information sheet. Of these, 32 replied and completed phone screening. Six were excluded due to screen failure (met exclusion criteria). Twenty-six participants were recruited (long COVID n=16 and controls n=10). Two participants (1 long COVID and 1 control) did not complete the study since they could not tolerate the mask for spirometry, 1 long COVID participant was excluded

100 during the study visit due to identification of cardiac disease (valve disease or non-101 benign arrythmia) and 1 participant was excluded between visits due to diagnosis of 102 gout (control). The final sample size was 14 participants with long COVID and 8 103 controls (recovered from initial viral infection within 4 weeks without ongoing 104 symptoms). Data sets from six healthy participants from a previous study (NHS REC 105 numbers: 17/SW/0171 and 18/SW/0241), completed before the SARS-CoV-2 106 pandemic using the same methods, equipment, and location (clinical room) were 107 added to the control group. These participants were identified based on age, sex, 108 and body mass index (BMI) so that they matched the participants in the long COVID

109 study.

110 Participant demographics are shown in Table 1. Age, BMI, height, and body mass

111 were similar between the control and long COVID groups (P>0.05). Clinic systolic

blood pressure (SBP), diastolic BP (DBP) and heart rate (HR), were not different

113 between groups (P>0.05).

114 All participants who had COVID-19 were first infected from April 2020 to December

115 2021, when the dominant variants of SARS-CoV-2 were the original virus, Alpha,

116 Delta, and Omicron. The average number of days since first infection to the study

117 visit, in the long COVID and control groups, were similar (Table 1, P=0.1006). As per

the exclusion criteria, none of the participants were hospitalised (admitted) for

119 COVID-19 and had a previous positive PCR test at the time of the initial infection or

120 were seropositive for SARS-CoV-2 antibodies (see inclusion/exclusion criteria in

121 methods). The initial infection caused mild to moderate symptoms in all participants.

122 Table 2 outlines the most common ongoing symptoms previously reported^{9,31,32} and

123 the percentage of the long COVID participants in this study reporting these

symptoms. Long COVID participants reported at least 3 symptoms, with the most

125 common symptoms being dyspnoea at rest and on exertion, extreme fatigue, "brain126 fog" and chest pain.

127 Ten out of the 14 long COVID participants had been seen in a cardiology outpatient

128 long COVID clinic at a UK based University Hospital NHS Trust, where structural

129 cardiac disease (e.g., myocarditis, heart failure, ischaemia) had been excluded. All

- 130 the participants reporting chest pain were reviewed in a cardiology clinic, which was
- 131 diagnosed as non-cardiac in origin. None of the long COVID participants (or controls)

- 132 had been diagnosed with pre-existing cardiovascular or pulmonary diseases. Four of
- 133 the long COVID participants had been prescribed ivabradine in the cardiology
- 134 outpatient long COVID clinic. These participants stopped taking ivabradine 48 hours
- 135 before their study visits (plasma half-life: 2 hours and effective half-life: 11 hours).
- 136 Severe asthma was an exclusion criterion, however 2 controls and 6 long COVID
- 137 participants had been previously diagnosed with mild asthma (before COVID). All
- 138 participants had a normal resting 12-lead ECG, which was completed as part of the
- 139 study screening process. Twelve of the 14 long COVID participants self-reported
- having a chest x-ray, all of which were normal. Finally, Supplementary Table 1
- 141 provides information of drugs prescribed in both groups.

Demographics	Controls (n=14)	Long COVID (n=14)	P-value
Sex (M/F)	3/11	2/12	-
Age (years)	35 ± 13	42 ± 12	0.1195
BMI (kg/m²)	24.5 ± 4.9	26.9 ± 5.3	0.2140
Height (cm)	166 ± 5	167 ± 7	0.5543
Body mass (kg)	67.2 ± 12.9	75.1 ± 16.3	0.1573
Received all recommended	100%	100%	-
COVID-19 vaccinations at time			
of study (%)			
Time since initial infection	473 (265-543)	534 (400-709)	0.1006*
(days) [median (IQR)]			
Clinic BP			
SBP (mmHg)	121 ± 9	131 ± 17	0.0732
DBP (mmHg)	75 ± 7	83 ± 13	0.0594
HR (beats/min)	69 ± 12	75 ± 12	0.1895
Resting lung function			
n	11	14	
FEV ₁ (z-scores)	-0.32 ± 0.92	-0.90 ± 1.23	0.2109
FVC (z-scores)	-0.56 ± 1.01	-1.03 ± 0.86	0.2279
FEV ₁ /FVC (z-scores)	0.60 ± 0.95	0.21 ± 1.13	0.3727
FEF _{75%} (z-scores)	0.61 ± 1.01	0.43 ± 0.77	0.6191

142 Table 1 - Demographic, spirometry, and SARS-CoV-2 infection data.

- 143 *Mann Whitney U. BMI; body mass index, IQR; interquartile range, BP; blood
- 144 pressure, SBP; systolic blood pressure, DBP; diastolic blood pressure, HR; heart
- 145 rate, FEV₁; forced expiratory volume in 1 second, FVC; forced vital capacity, FEF_{75%};
- 146 forced expiratory flow after 75% of the FVC has been exhaled. Note that the control
- 147 group includes data from 6 participants data who took part in studies in the same
- 148 laboratory before the pandemic and did not have COVID-19. Thus, the data
- 149 pertaining to vaccines and infections is for the 8 participants recruited who had
- 150 COVID-19 infection but did not develop ongoing symptoms.
- 151 Table 2 Common ongoing symptoms reported in post COVID-19 syndrome and
- the % of participants in the present study, self-reporting these symptoms.

Symptoms	Long COVID (n=14)
At least 3 symptoms	100%
Dyspnoea on exertion	92%
Dyspnoea at rest	86%
Brain fog	86%
Fatigue	79%
Chest pain	50%
Palpitations or tachycardia	36%
Dizziness	36%
Post-exertional malaise	36%
Muscle or joint pain	21%
Oedema in extremeties	14%
Nausea	14%
Chronic dry cough	14%
Impaired taste or smell	7%
Alopecia	7%
Chronic fever	0%
Diarrhoea	0%

153

154 *Resting spirometry*

155 Spirometry data are summarized in Table 1 and are presented as z-scores with a

156 normal z-score being between $\pm 1.64^{33}$. There were no differences between the two

157 groups for FEV₁ (forced expiratory volume in 1 second), FVC (forced vital capacity),

- 158 FEV₁/FVC and FEF_{75%} (forced expiratory flow after 75% of the FVC has been
- 159 exhaled; P>0.05). No participants had an FEF_{75%} smaller than -1.64 z-score,
- 160 therefore excluding small airway disease. One control subject and 3 long COVID
- 161 participants had a reduced FEV₁ and FVC with a normal FEV₁/FVC ratio, suggestive
- 162 of a restrictive ventilatory defect. One long COVID participant had a reduced FEV₁
- 163 and FVC, with an FEV₁/FVC ratio consistent with an obstructive ventilatory defect
- 164 (z-score = -3.25) indicating severe airflow obstruction (z-score = -3.85)³³.
- 165 Sit to standing blood pressure test
- To check for orthostatic intolerance in both groups, a sit-to-standing test (like that
 used in the HYVET study^{34,35}) was completed (3 mins of standing). Sit-to-stand was
 completed in all long COVID participants and 8 of the controls. BP was measured at
 seated rest, immediately after standing, 1 min, 2 mins and 3 mins of standing.
 According to HYVET study guidelines, a fall in SBP>15 and DBP>7 mmHg was used
- as a diagnosis of orthostatic intolerance. During standing, the mean SBP and DBP
- did not fall by more than 15 and 7 mmHg in either group at any time point ³⁴
- 173 (Supplementary Figure 2; Supplementary Table 2 for mean change data). Two
- 174 control participants had a fall in SBP >15 or DBP >7 mmHg, and 1 participant from
- the long COVID group met this criterion (supplementary figure 2). Mean data at each
- timepoint were analysed using a mixed model ANOVA. Interestingly, we found that
- 177 the increase in HR was larger in the control group versus the long COVID group
- 178 (main Time*Group effect; P=0.0258, see supplementary results for ANOVA details
- 179 and figure 2).
- 180 Resting cardiopulmonary data
- 181 The resting HR, BP, minute ventilation, tidal volume and breathing frequency were 182 similar between groups (Table 3, P>0.05). Resting partial pressure of the end tidal 183 CO_2 (P_{ET}CO₂) was lower in the long COVID group (range: 22 to 34 mmHg versus 184 controls (range: 30-36 mmHg, Table 3, P=0.0378). The minute ventilation was 185 similar between groups despite a lower P_{ET}CO₂ in the long COVID group. This was 186 coupled with a higher ventilation for the volume of CO_2 expired (V_F/VCO₂ ratio, 187 P=0.0246); suggesting that there is some hyperventilation occurring at rest in the 188 long COVID group. There were no differences in the expiratory and inspiratory times, 189 or the ratio of inspiration to expiratory times between groups (P>0.05; Table 3 for

- 190 exact P-values). Interestingly, the tidal volume/inspiratory time ratio (V_T/Ti ; an index
- 191 of inspiratory flow³⁶) was 16% higher in the long COVID group versus the controls
- 192 (P=0.0483) indicative of increased inspiratory drive.

193 Table 3 - Resting cardiopulmonary variables in controls versus long C	COVID.
---------------------------------------------------------------------------	--------

Resting cardiopulmonary	Controls	Long COVID	P-value
data	(n=14)	(n=14)	
SBP (mmHg)	112 ± 9	118 ± 16	0.1603
DBP (mmHg)	75 ± 8	80 ± 16	0.1985
HR (beats/min)	76 ± 9	83 ± 11	0.0886
V _E (L/min)	9.2 ± 2.1	10.1 ± 2.8	0.3434
V ₇ (mL)	609 ± 115	659 ± 173	0.3546
f _B (breaths/min)	15 ± 3	16 ± 3	0.8938
Ti (secs)	1.65 ± 0.37	1.60 ± 0.41	0.7934
Te (secs)	2.86 ± 0.61	2.77 ± 0.81	0.7509
Ti/Te	0.59 ± 0.08	0.59 ± 0.12	0.9062
V ₇ /Ti	0.37 ± 0.07	0.43 ± 0.09	0.0483
P _{ET} CO ₂ (mmHg)	33.5 ± 2.6	30.9 ± 3.7	0.0378
VO ₂ (L/min)	0.25 ± 0.05	0.24 ± 0.05	0.5781
VCO ₂ (L/min)	0.22 ± 0.04	0.21 ± 0.05	0.8006
V _E /VCO ₂ ratio	42.2 ± 4.4	48.0 ± 8.3	0.0246

194 SBP; systolic blood pressure, DBP; diastolic blood pressure, HR; heart rate, VE; 195 minute ventilation, V_{T} ; tidal volume, f_{B} ; breathing frequency, Ti; inspiratory time, Te; 196 expiratory time, V_{T}/Ti ; inspiratory flow index, $P_{ET}CO_2$; end-tidal partial pressure of 197 carbon dioxide, VO₂; volume of inspired oxygen, VCO₂; volume of expired carbon 198 dioxide.

199

200

201

202 Cardiopulmonary exercise testing

203 Cardiopulmonary exercise testing (CPET) was completed on a cycle ergometer to

204 peak oxygen consumption (VO₂ peak) to assess exercise tolerance and identify any

205 breathing or cardiovascular abnormalities that might not be evident at rest. We also

wanted to understand whether any dysfunctional breathing (defined here as inappropriate hyperventilation or poor breathing efficiency characterised by elevated minute ventilation/volume of CO_2 expired (V_E/VCO₂) slopes¹⁷) during exercise could be linked to carotid chemoreflex hyperactivity in the long COVID group versus control.

211 To assess whether maximal effort was achieved and as an objective assessment of 212 the quality of the test, a respiratory exchange ratio>1.15, maximum predicted 213 HR>85%, rating of perceived exertion (RPE; 6-20 Borg Scale) of 17-20 and a 214 plateau in VO₂ were used. Overall, 86% of the control group and 86% of the long 215 COVID group achieved these criteria. Thus, differences between groups are likely 216 not due to differences in effort or quality of the CPET. In fact, the control group 217 reported a lower RPE at peak exercise (17; 17-18 (median, IQR)) versus the long 218 COVID group (19; 18-19, P=0.0081; Mann Whitney U). Table 4 shows the mean ± 219 SD (range) for all CPET variables. None of the participants desaturated during the 220 test (defined as $SpO_2 \ll 95\%$, where peak $SpO_2 \%$ was similar between groups), and 221 there were no exercise induced cardiac ischaemic changes observed on the 12-lead 222 ECG.

223 The VO₂ peak measured in L/min, mL/kg/min and as a % of peak predicted were 224 lower in the long COVID group versus controls (Table 4; P<0.05). Absolute VO₂ at 225 anaerobic threshold (AT) was also lower (P=0.0025), but the % of peak VO₂ at which 226 the AT occurred was similar between groups (P=0.6490), indicating normal 227 metabolic function. Along these lines there were no other indications of defects in 228 muscle metabolic pathways indicating no muscle metabolic limitations to VO₂ peak in 229 either group (i.e. normal peak respiratory exchange ratio (RER) and a normal VO₂/work rate relationship^{37,38} (Table 4). Maximum HR was lower in the long COVID 230 231 group versus controls, but there was no difference between groups when HR was 232 measured as the % of predicted maximum (P=0.1326). The slope of the HR plotted 233 against the %VO₂ peak was lower in the long COVID group (Table 4; P=0.0114) 234 versus controls indicating a blunted HR response to exercise and potentially some 235 degree of chronotropic incompetence. Heart rate at AT was also lower in the long 236 COVID group versus controls (P=0.0453). Finally, the peak oxygen pulse (VO₂/HR) 237 was lower in the long COVID group versus controls, indicating a cardiovascular 238 limitation to exercise. Despite this, the HR recovery at 1 min was similar between

groups (P=0.4653); indicating that parasympathetic engagement post-exercise in the
 long COVID group was similar to control.

The VCO₂ at peak was lower in the long COVID group (Table 4; P=0.0477), whereas
minute ventilation, tidal volume and breathing frequency at peak were similar
between groups (Table 4, P>0.05). Supplementary figure 3 shows the minute
ventilation versus the VCO₂ and VO₂ at rest, AT, and peak exercise in both groups.
The mean breathing reserve (max minute ventilation/predicted maximal voluntary
ventilation (calculated as FEV1 * 40) was similar between groups (P=0.8708). Thus it

- 247 is likely that the lower peak VO_2 in the long COVID group is not a result of pulmonary
- 248 mechanical limitations^{39,40}.
- 249 The V_E/VCO₂ ratio at peak (ANOVA; P=0.0051) and at AT (P=0.0477) was higher in
- the long COVID group versus control (see Supplementary figure 3 for ANOVA details
- and V_E/VCO_2 ratio plotted against the VO₂ at rest, AT, and peak exercise). The
- V_E/VCO_2 slope (Table 4, P=0.0008) and the V_E/VCO_2 nadir (P=0.0020) during
- 253 exercise were also higher in the long COVID group versus controls indicating lower
- breathing efficiency (a higher minute ventilation to remove a given volume of CO₂)
- 255 indicating hyperventilation at any point during exercise (Figure 1 for example slopes
- 256 (raw data) in a control and long COVID participant). Thirteen percent of the control
- group had a V_E/VCO_2 slope higher than the normal range (20-30^{41,42}) versus 88% in
- the long COVID group. Finally, the $P_{ET}CO_2$ was lower at the AT and at peak exercise
- in the long COVID group versus the control group (time*group effect; P=0.0119,
- 260 mixed model ANOVA), but the magnitude of rise of the P_{ET}CO₂ from rest to AT and
- from rest to peak exercise was the same in both groups (P=0.0904, supplementary
- 262 figure 4, mixed model ANOVA).
- 263
- 264
- 265
- 266
- 267

- 268 Table 4 Cardiopulmonary exercise testing data in the control and long COVID
- 269 groups.

CPET data	Controls (n=14)	Long COVID (n=14)	P-value
HR at peak (beats/min)	170 ± 17	158 ± 18	0.0619
(% predicted)	97 ± 6	92 ± 9	0.1326
VO₂at peak (L/min)	1.78±0.57	1.40±0.34	0.0378
(mL/kg/min)	26.7±7.4	18.6±4.7	0.0015
(% predicted)	91±18	76±18	0.0340
HR/%VO ₂ slope	1.00 ± 0.15	0.77 ± 0.26	0.0114
RER at peak	1.28 ± 0.11	1.27 ± 0.09	0.7483
RPE at peak (median, IQR)	17 (16-18)	19 (18-19)	0.0081*
Dyspnoea at peak (median,	5 (4-8)	8 (5-9)	0.0515*
IQR)			
SpO ₂ (%) at peak	99 ± 1	99 ± 1	0.8966
VCO ₂ at peak (L/min)	2.29 ± 0.83	1.76 ± 0.52	0.0477
P _{ET} CO ₂ at peak	39.6±4.7	33.6±3.8	0.0007
O ₂ pulse peak (mL/beat)	10.6 ± 2.8	8.9 ± 2.0	0.0650
Peak SBP (mmHg)	177 ± 21	171 ± 26	0.5115
Peak DBP (mmHg)	88 ± 12	90 ± 15	0.6286
V _E at peak (L/min)	71.5±29.2	66.4±22.4	0.6012
Breathing reserve	43 ± 18	42 ± 24	0.8708
f_B at peak (breaths/min)	36 ± 10	37 ± 9	0.8705
V⊤at peak (L)	1.98 ± 0.47	1.83 ± 0.40	0.3440
V _E /VCO ₂ ratio at peak	31.4 ± 4.9	38.7 ± 5.4	0.0005
V _E /VO ₂ ratio at peak	39.8 ± 7.6	48.4 ± 8.6	0.0095
V _E /VCO ₂ slope	27.7 ± 4.8	37.8 ± 4.4	0.0003
Nadir V _E /VCO ₂	25.0 ± 2.4	30.1±5.0	0.0020
VO ₂ at AT (mL/kg/min)	18.7 ± 5.6	12.6 ± 4.3	0.0025
(% of VO ₂ peak)	68 ± 10	66 ± 13	0.6490
P _{ET} CO ₂ at AT (mmHg)	44 ± 4	38 ± 6	0.0041
V _E /VCO ₂ at AT	25.5 ± 2.4	30.4 ± 5.4	0.0042
HR at AT (beats/min	132 ± 13	121 ± 15	0.0453
(% of peak HR)	76 ± 5	77 ± 8	0.6181

Δ from rest (beats/min)	61 ± 18	38 ± 16	0.0009
VO ₂ /WR slope	8.2 ± 1.2	8.2 ± 1.5	0.9283
Heart rate recovery 1 min	19±7	17±5	0.4635
(beats/min)			

270 HR; heart rate, VO₂; volume of inspired oxygen, RER; respiratory exchange ratio,

271 RPE; rating of perceived exertion, SpO₂; oxygen saturation, VCO₂; volume of expired

272 carbon dioxide, SBP; systolic blood pressure, DBP; diastolic blood pressure, VE;

273 minute ventilation, Bf; breathing frequency, TV; tidal volume, VE/VCO₂; ventilatory

efficiency, AT; anaerobic threshold, P_{ET}CO₂; partial pressure of end-tidal carbon

275 dioxide, WR; work rate.

276

277 Hypoxic ventilatory response

278 Figure 1A shows examples carotid chemoreflex tests in a control and a long COVID 279 participants and the resultant hypoxic ventilatory responses (calculated from the 280 minute ventilation) in these participants (Figure 1B). The hypoxic ventilatory 281 response (minute ventilation response to reductions in SpO_2 %) was elevated in the long COVID (-0.44 \pm 0.23 l/min/ SpO₂%, R²=0.77 \pm 0.20) group compared to controls 282 (-0.17 ± 0.13 l/min/SpO2%, R²=0.54±0.38, Figure 2A, P=0.0007); thus, for a given 283 284 decrease in SpO₂, the participants with long COVID had a greater increase in minute 285 ventilation. This was driven by a greater increase in tidal volume (Figure 2B) in the 286 participants with long COVID rather than a greater increase in breathing frequency 287 compared to the controls (Figure 2C). Taken together this indicates that the 288 participants with long COVD have an elevated carotid chemoreflex sensitivity to 289 hypoxia. 290 There was no difference in the HR response to hypoxia (Figure 2D) between groups

291 (control; -0.66 ± 0.35 beats/min/ SpO₂% versus long COVID; -0.58 ± 0.60

beats/min/SpO2%, P=0.5978). Additionally, there was no difference in the SBP or

293 DBP response to hypoxia between groups (Figure 2E and 2F). The BP response to

294 hypoxia was variable between individuals with some participants showing a

295 depressor response to hypoxia and others showing a pressor (most common, where

- the slope of the regression is negative in figure 2E and 2F) or biphasic response to
- 297 hypoxia.

- 298 The hypoxic ventilatory response was correlated with the V_E/VCO₂ slope during
- exercise (r=0.54, P=0.0037); indicating that the high carotid chemoreflex sensitivity
- 300 in the long COVID participants may partially explain the higher V_E/VCO_2 slope
- 301 (poorer breathing efficiency) during exercise. Therefore, the carotid chemoreflex may
- 302 play an important role in driving hyperventilation or poor breathing efficiency during
- 303 exercise. Targeting the carotid body or the carotid chemoreflex could be helpful in
- 304 improving ongoing symptoms in participants with long COVID and improving
- 305 exercise tolerance.





Figure 1 - A) Example carotid chemoreflex test in a control (solid line) and long COVID (dotted line) participants. Data shows the raw SpO₂ response to nitrogen exposure (bottom panel) and the resultant tidal volume, breathing frequency, and minute ventilation responses. The minute ventilation (average of the largest 2 consecutive breaths) is plotted against the nadir SpO₂ for each nitrogen exposure²¹ (panel B). The resultant slope of the linear regression is the hypoxic ventilatory response. Panel C shows the minute ventilation (V_E) plotted against the volume of expired carbon dioxide (VCO₂) for each breath during exercise in the same 2 participants. The slope of the regression is the V_E/VCO₂ slope and is used as a measure of breathing efficiency.

313



314

Figure 2 - The hypoxic ventilatory response based on A) minute ventilation, B) tidal volume (V $_{T}$) and C) breathing frequency (f_B). There was a higher hypoxic ventilatory response based on minute ventilation and tidal volume in the participants with long COVID (n=14) versus control (n=14). Panels D, E and F show the heart rate, systolic and diastolic blood pressure hypoxic responses. Data are the slope of the linear regression where SpO₂% was plotted against the heart rate, and BP during each hypoxic exposure. There was no difference in the HR or BP response to hypoxia between groups.

322

323 Discussion

324 The pathophysiological mechanisms driving ongoing symptoms in patients with long COVID,

325 after an initial mild infection, are unclear. Here we show for the first time that carotid

326 chemoreflex sensitivity is amplified in non-hospitalised patients with long COVID (versus a

- 327 control group) and that this was correlated with hyperventilation and poor breathing
- 328 efficiency during exercise. Elevated carotid chemoreceptor activity could explain several of
- the ongoing symptoms experienced by patients living with long COVID.
- 330

331 The hyperventilatory state of long COVID

332 In this population of participants with long COVID, we show that despite similar lung 333 function (resting spirometry and ventilatory reserve during exercise) to the control group, 334 these participants hyperventilate at rest and during exercise. At rest, this is evidenced by a 335 similar minute ventilation compared to control despite a lower resting P_{ET}CO₂. Resting 336 levels of arterial CO_2 provides the key stimulus for respiratory drive, mainly via the central 337 chemoreceptors.⁴³ Reductions in P_{FT}CO₂ indicate decreases in PaCO₂ ^{44,45} which is a 338 stimulus to lower ventilation; however, this has not occurred in the long COVID participants 339 since their level of ventilation was the same as the controls suggesting a resetting of 340 chemoreceptor set-point for breathing. If resting P_{FT}CO₂ levels were restored to normal 341 control levels, it is possible that minute ventilation would be greater in the long COVID 342 group. Additionally, the V_E/VCO_2 ratio at rest is higher in the long COVID participants, 343 showing that they are breathing more to remove the same volume of CO₂ as controls. 344 Altered V_E/VCO_2 ratio (and $P_{ET}CO_2$) could result from changes to gas exchange between 345 the alveoli and pulmonary circulation. However, we found that during exercise the 346 magnitude of the rise in P_{ET}CO₂ was the same in the long COVID participants versus the 347 controls. During exercise (with a normal gas exchange) P_{ET}CO₂ rises and peaks around 348 anaerobic threshold. When gas exchange is impaired by abnormal ventilation or perfusion 349 of the lung, the $P_{FT}CO_2$ will show smaller rises, no rise, or even decrease as seen in COPD, 350 heart failure and pulmonary hypertension⁴⁶. As such, the similar rise in P_{ET}CO₂ with 351 exercise in long COVID patients and control participants suggests no differences in gas 352 exchange between these groups. However, we acknowledge that this needs to be 353 confirmed with gas diffusion studies.

We also found evidence of elevated resting V_7/Ti , an index of inspiratory flow, in the long COVID group versus the control group. The V_7/Ti is used as surrogate of primary neural drive for inspiration³⁶ and thus could indicate a higher 'inspiratory drive' at rest in the long COVID participants which may contribute to their feelings of dyspnoea. High inspiratory flow can also indicate changes in airway mechanics⁴⁷, however, this is unlikely in the long

359 COVID group, since resting lung function (spirometry) was similar between groups. During

360 exercise, hyperventilation or poor breathing efficiency was also evidenced by elevated

 V_E/VCO_2 slopes and an elevated V_E/VCO_2 ratio at anaerobic threshold and peak exercise.

362 Since the carotid chemoreflex plays an important part in the control of breathing both at rest

- and exercise (including inspiratory drive⁴⁸); it is possible that it is contributing to
- 364 hyperventilation in long COVID.
- 365

366 *Carotid chemoreflex*

The mammalian carotid chemoreflex is a protective reflex that contributes to ventilatory and 367 cardiovascular control⁴⁹. In addition to signalling the need for increased ventilation during 368 369 hypoxia (and other stimuli¹⁹), the carotid body chemoreceptors contribute to resting ventilatory drive, as demonstrated by their tonic activity in humans and animal models^{48,50}. 370 371 It is well established that certain disease states exhibit exaggerated carotid chemoreflex sensitivity²⁰ and tonicity¹⁸. Given that elevated carotid chemoreflex sensitivity measured by 372 373 the hypoxic ventilatory response predicts symptom burden, exercise intolerance, dyspnoea. and hyperventilation in heart failure^{21,51}, we aimed to assess carotid chemoreflex sensitivity 374 375 in long COVID. The hypoxic ventilatory response was 145% higher in the long COVID 376 group versus age-, BMI- and sex-matched controls indicating amplified carotid 377 chemoreceptor sensitivity in the long COVID group. The higher hypoxic ventilatory 378 response was observed despite a lower resting $P_{ET}CO_2$ in the long COVID group even though hypocapnia normally depresses carotid chemoreflex sensitivity to hypoxia⁵². The 379 380 hypoxic ventilatory response was in fact similar to that measured in a group of patients with 381 heart failure reduced ejection fraction in our lab (-0.44 ±0.23 L/min/SpO2% versus -0.48± 382 0.30 L/min/SpO2%; mean ± SD) using the same equipment before March 2020 (see 383 supplementary Figure 5). The elevated hypoxic ventilatory response in the long COVID 384 participants was driven by amplified responses in tidal volume rather than breathing 385 frequency, which supports previous reports in humans where the increase in minute 386 ventilation during mild hypoxia is driven mainly by increases in tidal volume⁵³. 387 The hypoxic ventilatory response was correlated with the V_F/VCO_2 slope, so that a person

388 with high chemoreflex sensitivity had a higher V_E/VCO₂ slope (or vice versa). This suggests

389 that elevated carotid chemoreflex sensitivity may partially explain reduced breathing

390 efficiency and hyperventilation during exercise in participants with long COVID^{14,15,17}. In fact,

- 391 breathing efficiency was poor in some of the participants in this study; 64% of the long 392 COVID group had a V_E/VCO_2 slope >34 (versus only 7% (one person) in the control group), which is a powerful prognostic indicator of future outcomes for people with heart failure⁵⁴. It 393 394 is possible that in long COVID the carotid chemoreflex has a similar function as that 395 described heart failure, partially explaining the dysregulated breathing and feelings of 396 breathlessness in patients with ongoing symptoms after their initial mild infection. Elevated 397 V_E/VCO_2 slopes are also caused by increased dead space ventilation due to 1) inadequate 398 aeration of the alveoli and 2) poor perfusion of the aerated lung spaces, affecting gas 399 exchange. However, in this study there was no evidence of mechanical lung or small airway 400 issues (due to a similar prevalence of normal breathing reserve in the two groups and 401 similar resting spirometry between the groups). No obvious evidence of gas exchange 402 issues were observed either, because the $P_{FT}CO_2$ during exercise (to AT) increased by a 403 similar magnitude in the participants with long COVID versus the controls.
- 404 Finally, the resting $P_{FT}CO_2$ was <30 mmHg in 4 participants with long COVID. Low $P_{FT}CO_2$ 405 causes similar symptoms as those often experienced by patients with long COVID including feelings of brain fog (due to poor cerebral perfusion) and paraesthesia ⁵⁵. The level of 406 $P_{FT}CO_2$ however did not reach approve threshold levels ⁵⁶ in any patients because there 407 408 were no apnoeas at rest and no evidence of periodic breathing patterns⁵⁷. Low resting 409 $P_{ET}CO_2$ and hyperventilation is a hallmark of hyperventilatory syndrome which has been cited as a cause of ongoing in symptoms in some cohorts of patients with long COVID⁵⁸. It 410 411 is possible that problems with breathing at rest and during exercise, leading to lower 412 $P_{FT}CO_2$ levels and manifesting as hyperventilation syndrome could be partially driven by 413 the carotid chemoreflex in patients with long COVID.
- 414 Mechanisms
- 415 Possible mechanisms of increased carotid chemoreceptor sensitivity after SARS-CoV-2
- 416 infection include local changes within the parenchyma of the carotid body and/or
- 417 dysfunction occurring in medullary regions that process afferent sensory information and
- 418 control efferent ventilatory responses.
- In the acute phase of the infection, local viral and immune cell invasion of the carotid body²⁵
- 420 could disrupt normal functioning, potentially via immune cells destroying infected glomus
- 421 cells explaining silent hypoxia in some patients²³. In the long-term these cells are likely
- 422 replaced but there is the possibility of long-term local inflammation and disruption of ACE1

423 and ACE2 balance leading to elevated carotid chemoreceptor drive. Additionally, since the 424 carotid bodies are highly sensitive to disturbances in perfusion, any blood flow disruption caused by microthrombi and endothelial dysfunction²⁵ could elevate carotid body activity⁵⁹. 425 426 It is also possible that dysfunction of the petrosal ganglion, which carries afferent sensory 427 input into the brainstem, causes hyper-reactivity in the carotid chemoreflex. Of note, the 428 petrosal ganglion participates in mediating taste signals in the brain. However, only 7% of 429 our long COVID participants reported ongoing impaired sense of taste and smell ¹¹. 430 Additionally, inflammation or neuronal damage in the medullary regions mediating afferent 431 signals from the carotid body could contribute to increased chemoreceptor drive. Along 432 these lines there is evidence from animal models that the original SARS-CoV infiltrates medullary brain regions⁶⁰, but there is no strong evidence of this occurring with existing 433 434 variants of SARS-CoV-2.

435 Finally, some evidence suggests the SARS-CoV-2 may affect mitochondrial function⁶¹. The

436 glomus cells in the carotid body have unique mitochondria, which are important for O₂

437 sensing⁶². Any mitochondrial dysfunction in glomus cells could lead to augmented

438 chemoreflex activity⁶². Since mitochondrial dysfunction could occur in any organ, the

- exercise intolerance and hyperventilation observed in long COVID could also be driven, for
 example, by the metaboreceptors in skeletal muscle due to poor mitochondrial function and
- 441 this needs to be examined.

442 Limitations

443 Firstly, the control group are a combination of prospectively recruited participants who 444 recovered from a SARS-CoV-2 infection in <4 weeks, and participants who were 445 retrospectively identified from our previous studies (all measures were taken using the 446 same equipment, procedures, and site). Thus 6 of the controls did not have a previous 447 SARS-CoV-2 infection. We cannot rule out that SARS-CoV-2 infection has long lasting 448 effects of the cardiopulmonary system even if individuals recover with no ongoing 449 symptoms. Secondly, we measured the carotid chemoreflex sensitivity using poikilocapnic 450 hypoxia, thus P_{FT}CO₂ decreased after each hypoxic exposure (due to ventilatory 451 adjustments). However, it is unlikely that this affected the ventilatory response to hypoxia 452 because 1) the $P_{FT}CO_2$ decreased only after the breaths that were used as measurements 453 for ventilation and thus could not affect the data and 2) we waited for the PFTCO₂ to return 454 to baseline after each hypoxic exposure. Thirdly, this was a single site study with a small

455 sample size and thus needs to be evaluated in a larger population of patients with long

456 COVID. Finally, although we see evidence of elevated carotid chemoreceptor sensitivity in

457 patients with long COVID, we need to evaluate whether dampening down the hyperreflexia

458 helps to improve symptoms.

459 Implications

460 Here we show for the first time that patients with long COVID have elevated carotid

- 461 chemoreceptor sensitivity and that this is correlated with poor breathing efficiency or
- 462 hyperventilation during exercise. Interventions that temper carotid body excitability could be
- 463 explored as a treatment option for long COVID. Previously our group had shown that P2X3

464 receptors in the carotid body can be targeted to reduce carotid chemoreflex hyperreflexia in

465 an animal model of hypertension¹⁸ and heart failure⁶³, and could be a viable target in

466 humans with long COVID. Gefapixant, an oral P2X3 receptor antagonist, has recently

467 demonstrated efficacy and an acceptable safety profile in chronic cough in phase 3 clinical

468 trials⁶⁴. P2X3 receptors could therefore be a viable target in humans with long COVID.

469

470 Methods

471 Design

472 This was a single-site case-control study.

473 Participants

474 Ethical approval for the study was granted by South Central Hampshire NHS Research
475 Ethics Committee (21/SC/0260) and the Health Research Authority. Participants gave their

476 written informed consent. All participants were asked to abstain from intense exercise and

477 alcohol consumption 24 hours before the study. All experimental protocols conformed to the

478 Declaration of Helsinki. Inclusion criteria for all participants were; aged 18-80 years and a

- 479 positive SARS-CoV-2 antibody test before vaccination, or a positive COVID-19 PCR
- 480 antigen swab test. Long COVID participants had received a diagnosis of long COVID,
- 481 where symptoms developed during or after an infection consistent with COVID-19 and
- 482 continued for more than 12 weeks (and could not be explained by an alternative diagnosis)
- 483 as per NHS (UK) National Institute for Health and Care Excellence guidelines⁶⁵.

Participants without long COVID had symptoms lasting less than 4 weeks after their initialinfection. See the online-only Supplement for exclusion criteria.

486 Experimental protocol

487 Participants attended the NIHR Bristol Clinical Research facility for 2 studies, completed at

488 the same time of day, and the laboratory conditions were at a set temperature (22°C). In

489 visit one, informed consent, in-depth medical history, clinic blood pressure assessment, sit-

- 490 to-stand test for orthostatic intolerance, lung function tests (spirometry), 12-lead ECG,
- 491 pregnancy tests and a symptom limited incremental cardiopulmonary exercise test were
- 492 completed. The second visit involved resting ventilation and cardiovascular measurements
- 493 followed by carotid chemoreflex assessment via the hypoxic ventilatory response.

494 Procedures

495 *Clinic blood pressure:* Participants rested in a chair for 10 minutes prior to clinic BP being

496 assessed (Omron, 705IT, Omron Healthcare, Kyoto, Japan). Clinic BP was assessed in-line

497 with European Hypertension Society Guidelines⁶⁶

498 Orthostatic intolerance was assessed using a sit-to-stand test using the HYVET protocol³⁴

499 where BP was measured when sitting, immediately upon standing, and after 1, 2 and 3

500 minutes of standing.

501 Resting spirometry: Resting spirometry was used to assess lung function, to ensure no

502 mechanical lung function abnormalities were present. Spirometry (Ergostick, CPET system,

503 LoveMedical, UK) was completed in line with the joint American Thoracic and European

504 Respiratory Society guidelines ⁶⁷. The Global Lung Function Initiative (GLI) network

reference values were used to calculate the percentage of predicted values and z-scores 68 .

506 *12-lead ECG:* Resting 12-lead ECG was performed and checked by a Cardiologist at the

507 Bristol Heart Institute for any ECG abnormalities, and to clear participants to exercise.

508

509 Cardiopulmonary exercise testing

510 After acclimatisation to the facemask and sitting on the cycle ergometer, participants

511 completed a 5-minute steady state resting period followed by 3 minutes of unloaded cycling.

512 Participants then completed a continuous ramp incremental exercise test to volitional

513 exhaustion where work rate increased by 15-30 W depending on their physical ability.

514 Exercise tests were completed on an electronically braked cycle ergometer (Ergoselect 5; 515 Ergoline, Germany). Cardiorespiratory data were recorded using a metabolic measurement 516 system (Ergostik; LoveMedical, UK) with integrated 12-lead ECG and finger pulse oximetry 517 for heart rate and SpO₂% monitoring. Brachial arterial blood pressure was measured via an 518 integrated automated auscultatory blood pressure cuff (LoveMedical, UK. Ratings of 519 perceived exertion (6-20 Borg scale) and dyspnoea scores (modified Borg scale) were 520 obtained at rest, and every minute during exercise, and at the end of exercise. Peak 521 cardiopulmonary data were averaged over the last 30 seconds of exercise. The anaerobic 522 threshold was measured via the V-slope method and Dual Criterion methods as recommended by the American Thoracic Society guidelines ⁶⁹. The minute ventilation and 523 VCO₂ values from initiation to peak exercise were used to measure V_E/VCO₂ slope via least 524 525 squares linear regression⁷⁰.

526

527 Carotid chemoreflex assessment

528 Resting carotid chemoreceptor sensitivity tests were completed with participants in a semi-529 supine position with continuous monitoring of beat-to-beat blood pressure (Finapres), SpO₂ 530 (ear-lobe pulse oximeter; Radical-7; Masimo Corp, USA), heart rate (lead II of 3-lead ECG, 531 AD Instruments, Australia). Simultaneously, ventilation was measured via a facemask 532 attached to a one-way non-rebreathing circuit (Hans Rudolph, Inc., USA). The inhalation 533 part of the circuit delivered room air or 100% nitrogen gas (transiently) for carotid 534 chemosensitivity testing. The exhalation arm of the circuit was connected to a gas analyser 535 (Ad Instruments) and flow head (MLT3000L; AD Instruments) fitted with a differential 536 pressure transducer (FE141 Spirometer; AD Instruments) for the measurement of inspired 537 and expired fractions of O_2 and CO_2 , tidal volume, breathing frequency and minute 538 ventilation. All data were continuously monitored and recorded with a data acquisition 539 system (Powerlab 16/30: AD Instruments) and stored for subsequent analyses using 540 associated software (LabChart 8.0 Pro; AD Instruments).

541

542 The transient hypoxic ventilatory response test was used to measure the sensitivity of the

543 carotid chemoreflex ^{21,71}. After a period of quiet rest breathing room air (10 mins baseline),

the researcher added extra-nitrogen to the room air being delivered to the face-mask.

545 Nitrogen gas administration was controlled silently using a high-pressure electric valve. The

546 nitrogen blended into the room air was delivered for 2-8 breaths, followed by a 3-minute

547 recovery period or until ventilation and haemodynamic variables returned to baseline levels.

- 548 This was repeated 6-8 times to obtain a range of oxygen saturations (SpO₂: ~70–100%).
- 549 The average of the two largest consecutive breaths in the 1 minute proceeding the nitrogen
- 550 exposure was used to calculate the ventilatory response to reductions in SpO2%²⁰. The
- 551 hypoxic ventilatory response was evaluated as the slope of the linear regression relating
- the minute ventilation to the nadir of SpO_2 for each nitrogen exposure ^{20,71} (Figure 1B). The
- response of tidal volume and breathing frequency to reductions in SpO₂ were also
- evaluated in the same way as that for minute ventilation.
- 555 The peak heart rate and blood pressure was determined following each hypoxic challenge
- using a 3-beat rolling average and plotted against the nadir oxygen saturation. The hypoxic
- 557 heart rate (beats/min/%) and blood pressure (mmHg/%) were calculated as the slope of the
- simple linear regression obtained from baseline and the hypoxic challenges.
- 559

560 Statistical analysis

561 Statistical analyses were completed in GraphPad Prism (V9.5.1). Participant demographics, 562 resting spirometry, cardiopulmonary exercise and hypoxic ventilatory response data were

- 563 analysed using an independent samples t-test or Mann Whitney U test if data were not
- 564 normally distributed or were non-parametric. Where data are compared across multiple time
- 565 points between the groups, a mixed model ANOVA was used with a Bonferroni correction
- 566 for pairwise comparisons. Data are reported as mean ± standard deviation or median
- 567 (interquartile range) unless otherwise stated. A significance level of α <0.05 was used for all 568 analyses.
- 569
- 570 Disclosures
- 571 None.
- 572

573 Funding

574 This work was supported by the Elizabeth Blackwell Institute, University of Bristol and the

575 Bristol and Weston Hospitals Charity pump priming scheme.

576

577 Acknowledgements

- 578 Thank you to the participants who took part (despite their often-debilitating symptoms), the
- 579 study would not have been possible without them. Thank you also to the cardiology
- 580 research nurses who helped support this study.
- 581

582 References

- 583 1. Venkatesan, P. NICE guideline on long COVID. *Lancet Respir Med* **9**, 129 (2021).
- 5842.Thompson, E.J., *et al.* Long COVID burden and risk factors in 10 UK longitudinal studies and585electronic health records.
- Ahmad, I., *et al.* High prevalence of persistent symptoms and reduced health-related quality
 of life 6 months after COVID-19. *Front Public Health* **11**, 1104267 (2023).
- Augustin, M., *et al.* Post-COVID syndrome in non-hospitalised patients with COVID-19: a
 longitudinal prospective cohort study. *Lancet Reg Health Eur* 6, 100122 (2021).
- 5. O'Mahoney, L.L., *et al.* The prevalence and long-term health effects of Long Covid among
 hospitalised and non-hospitalised populations: a systematic review and meta-analysis. *eClinicalMedicine* 55, 101762 (2023).
- 5936.Huang, C., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a594cohort study. Lancet 397, 220-232 (2021).
- 595 7. Antonelli, M., *et al.* Risk factors and disease profile of post-vaccination SARS-CoV-2
- infection in UK users of the COVID Symptom Study app: a prospective, community-based,
 nested, case-control study. *Lancet Infect Dis* 22, 43-55 (2022).
- 598 8. (ONS), O.f.N.S. Prevalence of ongoing symptoms following coronavirus (COVID-19)
 599 infection in the UK: 2 February 2023. (ONS website, statistical bulletin, 2023).
- Whitaker, M., *et al.* Persistent COVID-19 symptoms in a community study of 606,434 peoplein England.
- Ballering, A.V., van Zon, S.K.R., Olde Hartman, T.C. & Rosmalen, J.G.M. Persistence of
 somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*400, 452-461 (2022).
- Alkodaymi, M.S., *et al.* Prevalence of post-acute COVID-19 syndrome symptoms at different
 follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect* 28, 657-666
 (2022).
- Davis, H.E., McCorkell, L., Vogel, J.M. & Topol, E.J. Long COVID: major findings,
 mechanisms and recommendations. *Nat Rev Microbiol* 21, 133-146 (2023).

610	13.	Davis, H.E., McCorkell, L., Vogel, J.M. & Topol, E.J. Long COVID: major findings,
611	15.	mechanisms and recommendations. <i>Nature Reviews Microbiology</i> 21 , 133-146 (2023).
612	14.	Durstenfeld, M.S., <i>et al.</i> Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-
613	17.	19 Symptoms in Adults: A Systematic Review and Meta-analysis. <i>JAMA Netw Open</i> 5 ,
614		e2236057 (2022).
615	15.	Singh, I., <i>et al.</i> Persistent Exertional Intolerance After COVID-19: Insights From Invasive
616	10.	Cardiopulmonary Exercise Testing. <i>Chest</i> 161 , 54-63 (2022).
617	16.	van Voorthuizen, E.L., van Helvoort, H.A.C., Peters, J.B., van den Heuvel, M.M. & van den
618		Borst, B. Persistent Exertional Dyspnea and Perceived Exercise Intolerance After Mild
619		COVID-19: A Critical Role for Breathing Dysregulation? <i>Phys Ther</i> 102 (2022).
620	17.	Frésard, I., et al. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in
621		'long COVID' patients with persistent dyspnoea. BMJ Open Respir Res 9(2022).
622	18.	Pijacka, W., et al. Purinergic receptors in the carotid body as a new drug target for
623		controlling hypertension. <i>Nat Med</i> 22 , 1151-1159 (2016).
624	19.	Iturriaga, R., Alcayaga, J., Chapleau, M.W. & Somers, V.K. Carotid body chemoreceptors:
625		physiology, pathology, and implications for health and disease. <i>Physiol Rev</i> 101 , 1177-1235
626		(2021).
627	20.	Ponikowski, P., et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients
628		with chronic heart failure. <i>Circulation</i> 104 , 544-549 (2001).
629	21.	Chua, T.P., et al. Clinical characteristics of chronic heart failure patients with an augmented
630		peripheral chemoreflex. Eur Heart J 18, 480-486 (1997).
631	22.	Lan, J., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
632		ACE2 receptor. Nature 581, 215-220 (2020).
633	23.	Villadiego, J., et al. Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19
634		Patients? Function (Oxf) 2, zqaa032 (2021).
635	24.	Villadiego, J., et al. Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19
636		Patients? Function 2(2020).
637	25.	Porzionato, A., et al. Case Report: The Carotid Body in COVID-19: Histopathological and
638		Virological Analyses of an Autopsy Case Series. Front Immunol 12, 736529 (2021).
639	26.	Lambermont, B., Davenne, E., Maclot, F. & Delvenne, P. SARS-CoV-2 in carotid body.
640		Intensive Care Med 47 , 342-343 (2021).
641	27.	Schultz, H.D. Angiotensin and carotid body chemoreception in heart failure. Curr Opin
642		<i>Pharmacol</i> 11 , 144-149 (2011).
643	28.	Allen, A.M. Angiotensin AT1 receptor-mediated excitation of rat carotid body chemoreceptor
644		afferent activity. J Physiol 510 (Pt 3), 773-781 (1998).
645	29.	Li, Y.L., et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic
646		outflow in chronic heart failure rabbits. Cardiovasc Res 71, 129-138 (2006).

647	30.	Rysz, S., et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-
648		angiotensin-aldosterone system. Nat Commun 12, 2417 (2021).
649	31.	Shah, W., Hillman, T., Playford, E.D. & Hishmeh, L. Managing the long term effects of covid-
650		19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 372, n136 (2021).
651	32.	Cervia, C., et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.
652		Nature Communications 13, 446 (2022).
653	33.	Sylvester, K.P., et al. ARTP statement on pulmonary function testing 2020. BMJ Open
654		Respir Res 7 (2020).
655	34.	Peters, R., et al. Orthostatic hypotension and symptomatic subclinical orthostatic
656		hypotension increase risk of cognitive impairment: an integrated evidence review and
657		analysis of a large older adult hypertensive cohort. Eur Heart J 39, 3135-3143 (2018).
658	35.	Peters, R., et al. Orthostatic hypotension and symptomatic subclinical orthostatic
659		hypotension increase risk of cognitive impairment: an integrated evidence review and
660		analysis of a large older adult hypertensive cohort. European Heart Journal 39, 3135-3143
661		(2018).
662	36.	Morgan, B.J., Adrian, R., Bates, M.L., Dopp, J.M. & Dempsey, J.A. Quantifying hypoxia-
663		induced chemoreceptor sensitivity in the awake rodent. Journal of applied physiology 117,
664		816-824 (2014).
665	37.	Riley, M.S., Nicholls, D.P. & Cooper, C.B. Cardiopulmonary Exercise Testing and Metabolic
666		Myopathies. Ann Am Thorac Soc 14, S129-S139 (2017).
667	38.	Riley, M.S., Nicholls, D.P. & Cooper, C.B. Cardiopulmonary Exercise Testing and Metabolic
668		Myopathies. Annals of the American Thoracic Society 14, S129-S139 (2017).
669	39.	Glaab, T. & Taube, C. Practical guide to cardiopulmonary exercise testing in adults. Respir
670		Res 23 , 9 (2022).
671	40.	Glaab, T. & Taube, C. Practical guide to cardiopulmonary exercise testing in adults.
672		Respiratory Research 23, 9 (2022).
673	41.	Balady, G.J., et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a
674		scientific statement from the American Heart Association. Circulation 122 , 191-225 (2010).
675	42.	Balady, G.J., et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a
676		scientific statement from the American Heart Association. Circulation 122 , 191-225 (2010).
677	43.	Guyenet, P.G. & Bayliss, D.A. Central respiratory chemoreception. Handb Clin Neurol 188,
678		37-72 (2022).
679	44.	Jones, N.L., Robertson, D.G. & Kane, J.W. Difference between end-tidal and arterial PCO2
680		in exercise. J Appl Physiol Respir Environ Exerc Physiol 47, 954-960 (1979).
681	45.	Jones, N.L., Robertson, D.G. & Kane, J.W. Difference between end-tidal and arterial PCO2
682		in exercise. Journal of applied physiology 47 , 954-960 (1979).

683	46.	Hansen, J.E., Ulubay, G., Chow, B.F., Sun, X.G. & Wasserman, K. Mixed-expired and end-
684	40.	tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in
685		patients with lung and heart diseases. <i>Chest</i> 132 , 977-983 (2007).
686	47.	Younes, M. Measurement and testing of respiratory drive, (Dekker, 1981).
687	48.	Blain, G.M., Smith, C.A., Henderson, K.S. & Dempsey, J.A. Contribution of the carotid body
688	40.	chemoreceptors to eupneic ventilation in the intact, unanesthetized dog. <i>Journal of applied</i>
689		physiology 106 , 1564-1573 (2009).
690	49.	Paton, J.F., et al. The carotid body as a therapeutic target for the treatment of
	49.	
691 602	50	sympathetically mediated diseases. <i>Hypertension</i> 61 , 5-13 (2013).
692	50.	Dejours, P. Chemoreflexes in Breathing. <i>Physiological Reviews</i> 42 , 335-358 (1962).
693	51.	Giannoni, A., et al. Combined Increased Chemosensitivity to Hypoxia and Hypercapnia as a
694		Prognosticator in Heart Failure. Journal of the American College of Cardiology 53, 1975-
695		1980 (2009).
696	52.	Smith, C.A., Harms, C.A., Henderson, K.S. & Dempsey, J.A. Ventilatory effects of specific
697		carotid body hypocapnia and hypoxia in awake dogs. Journal of applied physiology 82, 791-
698		798 (1997).
699	53.	Tipton, M.J., Harper, A., Paton, J.F.R. & Costello, J.T. The human ventilatory response to
700		stress: rate or depth? J Physiol 595, 5729-5752 (2017).
701	54.	Gitt, A.K., et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure
702		patients for high risk of early death. Circulation 106, 3079-3084 (2002).
703	55.	Gluck, S.L. Acid-base. Lancet 352, 474-479 (1998).
704	56.	Skatrud, J.B. & Dempsey, J.A. Interaction of sleep state and chemical stimuli in sustaining
705		rhythmic ventilation. J Appl Physiol Respir Environ Exerc Physiol 55, 813-822 (1983).
706	57.	Xie, A., Skatrud, J.B., Puleo, D.S., Rahko, P.S. & Dempsey, J.A. Apnea-hypopnea threshold
707		for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med 165, 1245-1250
708		(2002).
709	58.	Taverne, J., et al. High incidence of hyperventilation syndrome after COVID-19. J Thorac Dis
710		13 , 3918-3922 (2021).
711	59.	Ding, Y., Li, Y.L. & Schultz, H.D. Role of blood flow in carotid body chemoreflex function in
712		heart failure. <i>J Physiol</i> 589, 245-258 (2011).
713	60.	Netland, J., Meyerholz, D.K., Moore, S., Cassell, M. & Perlman, S. Severe acute respiratory
714		syndrome coronavirus infection causes neuronal death in the absence of encephalitis in
715		mice transgenic for human ACE2. J Virol 82, 7264-7275 (2008).
716	61.	Guntur, V.P., et al. Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid
717		Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC).
718		Metabolites 12 (2022).

719	62.	Holmes, A.P., Turner, P.J., Buckler, K.J. & Kumar, P. Moderate inhibition of mitochondrial
720		function augments carotid body hypoxic sensitivity. <i>Pflugers Arch</i> 468, 143-155 (2016).
721	63.	Lataro, R.M., et al. P2X3 receptor antagonism attenuates the progression of heart failure.
722		Nat Commun 14 , 1725 (2023).
723	64.	McGarvey, L.P., et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in
724		refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results
725		from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet
726		399 , 909-923 (2022).
727	65.	Excellence, N.I.f.H.a.C. COVID-19 rapid guideline: managing the long-term effects of
728		COVID-19. NG188 (2020).
729	66.	Williams, B., et al. 2018 Practice guidelines for the management of arterial hypertension of
730		the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).
731		Blood Press 27 , 314-340 (2018).
732	67.	Graham, B.L., et al. Standardization of Spirometry 2019 Update. An Official American
733		Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit
734		<i>Care Med</i> 200 , e70-e88 (2019).
735	68.	Quanjer, P.H., et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range:
736		the global lung function 2012 equations. <i>Eur Respir J</i> 40, 1324-1343 (2012).
737	69.	ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167,
738		211-277. (2003).
739	70.	Arena, R., et al. Development of a ventilatory classification system in patients with heart
740		failure. <i>Circulation</i> 115 , 2410-2417 (2007).
741	71.	Chua, T.P. & Coats, A.J. The reproducibility and comparability of tests of the peripheral
742		chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath
743		carbon dioxide response test in healthy subjects. <i>Eur J Clin Invest</i> 25 , 887-892 (1995).
744		